Invivoscribe NGS tests for lymphoproliferative diseases
Determine clonality and track clonal populations with the same reagents and workflow
Invivoscribe offers in vitro diagnostic products intended for next-generation sequencing (NGS) based identification and monitoring in patients suspected with having lymphoproliferative disease.
Leukemias and lymphomas originate from the malignant transformation of individual lymphoid cells. All leukemias and lymphomas generally share one or more cell-specific or “clonal” antigen receptor gene rearrangements. Therefore, tests that detect clonal rearrangements can be useful in the study of B- and T-cell malignancies.
Product is available in the following countries: